Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Affiliations

• ¹ Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
• ² Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
• ³ Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
• ⁴ Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA.
• ⁵ Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA.
• ⁶ Karyopharm Therapeutics, Newton, MA, USA.
• ⁷ Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
• ⁸ Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
• ⁹ Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
• ¹⁰ Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
• ¹¹ Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
• ¹² Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
• ¹³ Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
• ¹⁴ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. aribas@mednet.ucla.edu.